Stress Hormones Fuel Melanoma Growth, But Blood Pressure Drugs Might Help
A comprehensive review and meta-analysis examine whether repurposing common cardiovascular medications can block stress pathways and improve survival in skin cancer patients.
Stress hormones released by the body might be secretly helping skin cancer cells grow and hide from the immune system, according to a comprehensive new evaluation of existing data. Researchers looked at how beta-adrenergic receptors, which are proteins on cells that typically respond to adrenaline and stress, interact with malignant melanoma tumors. Although modern immunotherapy and targeted drugs have transformed cancer care, advanced melanoma still carries poor outcomes for many patients, prompting scientists to explore cost-effective repurposed medicines. A recent study published in Current Oncology Reports examined whether common blood pressure medications known as beta-blockers could block these stress pathways and improve patient survival.
Can Stress Hormones Accelerate Tumor Growth?
The human body responds to stress by releasing catecholamines, including adrenaline and noradrenaline, which bind to specific receptors on various cell types. Tumors often express these same stress receptors, allowing hormones to stimulate cancer cell proliferation, migration, and the formation of new blood vessels. In laboratory models, researchers have observed that chronic stress can increase tumor growth multifold by suppressing protective immune responses. Stress signaling dampens the activity of killer T cells and natural killer cells, which normally hunt down and destroy abnormal cells. Furthermore, stress pathways can upregulate proteins like PD-L1 on cancer cells, helping them evade detection by the immune system.
How Do Blood Pressure Medications Intervene?
Beta-blockers are traditional cardiovascular drugs prescribed to manage high blood pressure and abnormal heart rhythms by blocking stress receptor activation. Because cancer cells utilize these exact receptors, scientists hypothesized that beta-blockers might starve tumors of stress-driven growth signals. Laboratory experiments on melanoma cell lines demonstrate that drugs like propranolol and carvedilol can induce cell cycle arrest, trigger programmed cell death, and reduce the secretion of vascular endothelial growth factor, a protein that feeds tumor blood supplies. Additionally, these medications appear to reinvigorate exhausted immune cells within the tumor microenvironment, allowing cytotoxic T cells to infiltrate and attack the cancer more effectively.
What Did the Clinical Data and Meta-Analysis Reveal?
To determine if laboratory findings translate to human patients, the authors conducted a meta-analysis pooling data from 11 observational studies comprising multiple clinical cohorts. When analyzing overall survival across all patient groups, the pooled statistical estimate showed no definitive survival advantage for beta-blocker users. However, a significant protective signal emerged regarding progression-free survival for patients who took beta-blockers prior to their melanoma diagnosis. The authors emphasize that while laboratory evidence is compelling, observational clinical data remain mixed due to differences in study design, dosage variations, and potential biases in retrospective patient registries.
What Are the Limits and Next Steps for Research?
Many laboratory experiments utilize drug concentrations far higher than safe human blood plasma levels, raising questions about whether off-target mechanisms contribute to the observed anti-cancer effects. Furthermore, retrospective clinical studies cannot fully eliminate confounding factors such as underlying cardiovascular conditions or exact treatment timing. To settle these uncertainties, the research team advocates for rigorous, double-blind, placebo-controlled clinical trials. Future prospective studies should specifically evaluate non-selective beta-blockers as an adjuvant therapy alongside standard immunotherapy, establishing precise dosing windows and clear survival endpoints for patients battling advanced skin cancer.
The research was published in Current oncology reports on November 18, 2026.
This article has been fact checked for accuracy, with information verified against reputable sources. Learn more about us and our editorial process.
Last reviewed on .
Article history
- Latest version
Reference(s)
- Luong, Nguyen Dac Thuy., et al. “The Pathological Roles of β-adrenergic Receptors in Melanoma and Their Potential as Therapeutic Targets: A Systematic Review and Meta-analysis.” Current Oncology Reports, vol. 28, no. 1, November 18, 2026 Springer Science and Business Media LLC, doi: 10.1007/s11912-026-01868-2. <https://doi.org/10.1007/s11912-026-01868-2>.
Cite this page:
- Posted by Tariq Hassan